The Cyclowest group of companies consists of parent company Cyclowest Holdings Pty Ltd and one subsidiary, Cyclowest Pty Ltd.
Recent major developments across the group include:
12 Apr 2022
Cyclowest held a soil turning ceremony to mark the initiation of internal construction and fit-out of our facility in Bayswater, Perth WA. In attendance was WA Senator the Hon Linda Reynolds CSC (Federal government representative for the Modern Manufacturing Initiative) and David Dwyer, the Federal Liberal candidate for Perth.
Building Permit (Phase II) approved by City of Bayswater. Built are now cleared to start site construction, fit-out and establishment of a Good Manufacturing Practice (GMP) certified manufacturing laboratory facility.
14 Mar 2022
Cyclowest is pleased to announce the selection of Built to partner in the construction, fit-out and establishment of a Good Manufacturing Practice (GMP) certified manufacturing laboratory facility. This capability will support production of radiopharmaceuticals for both commercial manufacture and late-stage clinical trials in collaboration with local and international pharmaceutical companies. As the first in a network of such facilities, Cyclowest Perth will be positioned as a key player for new, longer-life diagnostic and therapeutic radiopharmaceuticals.
1 Mar 2022
Cyclowest has successfully completed a second capital raise to the sum of $7million AUD from original investors. Together with the generous support of the Australian Modern Manufacturing Grant, awarded in June 2021 valued at $2.6 million, Cyclowest has raised over $14 million AUD in the last 2 years to achieve its vision of developing modern cyclotron and GMP radiopharmaceutical facilities for Australian domestic and Asia Pacific markets.
6 Dec 2021
Phase I of facility construction, external shell construction, is completed. Phase II to follow with specialised internal construction and laboratory fit-out.
3 Dec 2021
Cyclowest and New Zealand Radiology Group are partnering to establish a new company for the design and operation of a facility to manufacture and distribute radiopharmaceuticals throughout New Zealand.
15 Nov 2021
Following a period of exploration, due diligence and purchase negotiation, land has been acquired for Cyclowest’s second facility, to be located in Far North Queensland.
12 Nov 2021
Cyclowest welcomes Angela Whittington to the Board of Directors. For further biographical details see the Team page.
1 Nov 2021
Cyclowest welcomes Adeesh Autar as an engineer for its first facility in Perth.
Cyclowest held a soil turning ceremony with WA Senator Ben Small (Commonwealth government representative for the Modern Manufacturing Initiative) to mark the start of construction at the Bayswater site.
8 Jul 2021
Cyclowest has been awarded $2.5 million from the Federal Government Modern Manufacturing Initiative to facilitate the production of new radiopharmaceuticals at the Perth facility.
Order placed for key laboratory equipment to enable production of radiopharmaceuticals for the Bayswater (Perth) facility.
27 Jan 2021
Reflecting its focus on an integrated Cyclowest brand, the board and shareholders unanimously approve renaming of parent holding company Molecular Technologies Pty Ltd to Cyclowest Holdings Pty Ltd.
08 Jan 2021
Stage 1 feasibility planning completed by APC.
04 Oct 2020
Order placed with GE for a fully shielded GE 890 PET-trace for the Bayswater (Perth) facility.
30 Oct 2020
Inaugural shareholders meeting held at Paragon Consulting. Full board membership confirmed by shareholders. Board meets thereafter on a monthly basis.
16 Oct 2020
Initial share subscription in Molecular Technologies – holding company of Cyclowest- successfully completed. Share offer oversubscribed. A number of local, interstate and international investors (mostly specialist doctors) invest over $6 million AUD.
23 Sep 2020
Dr Stephen Firmer and the team at APC chosen to undertake Stage 1 planning for the facility.
21 Sep 2020
DA approval to build site facility obtained from the Town of Bayswater.
16 Sep 2020
Investor briefing lead by Mr Thomas Tuchyna and Dr Nat Lenzo attended by over 20 local, interstate and international investors and consultants.